NEW YORK (GenomeWeb) – Cynvenio Biosystems announced today that it has raised $25.5 million in a Series B financing round. The money will help the company advance the clinical development and commercialization of its LiquidBiopsy platform, which allows analysis of both circulating tumor cells and circulating cell-free tumor DNA.

China-based Livzon Pharmaceutical Group led the funding round. Other investors included Greenwoods Private Equity Funds in Shanghai and Syno Capital in New York.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.